View Future GrowthMoberg Pharma 과거 순이익 실적과거 기준 점검 0/6Moberg Pharma 의 수입은 연평균 -59%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 9.4%의 비율로 증가했습니다. 매출은 연평균 15.8%의 비율로 감소해 왔습니다.핵심 정보-58.98%순이익 성장률-28.91%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률-15.84%자기자본이익률-3.87%순이익률-176.32%다음 순이익 업데이트13 Aug 2026최근 과거 실적 업데이트공시 • Nov 28+ 3 more updatesMoberg Pharma AB (publ) to Report Q2, 2026 Results on Aug 13, 2026Moberg Pharma AB (publ) announced that they will report Q2, 2026 results on Aug 13, 2026공시 • Oct 23+ 2 more updatesMoberg Pharma AB (publ) to Report First Half, 2025 Results on Aug 12, 2025Moberg Pharma AB (publ) announced that they will report first half, 2025 results on Aug 12, 2025공시 • Oct 11Moberg Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 11, 2025Moberg Pharma AB (publ) announced that they will report fiscal year 2024 results on Feb 11, 2025공시 • Aug 04+ 2 more updatesMoberg Pharma AB (publ) to Report Nine Months, 2024 Results on Nov 12, 2024Moberg Pharma AB (publ) announced that they will report nine months, 2024 results on Nov 12, 2024모든 업데이트 보기Recent updates공시 • May 23Moberg Pharma AB (Publ) Approves the Election of Board MembersOn May 21, 2026. Moberg Pharma AB (publ) held its Annual General Meeting. The Annual General Meeting resolved, in accordance with the proposal of the shareholder Noster Capital Master Fund Limited ("Noster Capital"), on election of Lars Johansson, Jack Bradley and Daniel Kaufman as board members, all for the period until the end of the next Annual General Meeting. Lars Johansson was elected, in accordance with the proposal of both the Nomination Committee and Noster Capital, as the new Chairman of the Board for the period until the end of the next Annual General Meeting. Lars Johansson, born 1966, has over 30 years of experience in pharmaceuticals and medtech. Lars Johansson has held leading roles within the J&J Group with increasing business area responsibility, including as CEO of the Nordic operations (Johnson & Johnson AB 2011-2019, and Janssen AB 2019-2021). Lars Johansson has also held board positions in Schain Research AB, ProstaLund AB, RLS AB, and Läkemedelsindustriföreningen (the Swedish Association of the Pharmaceutical Industry). Lars Johansson holds a master's degree in business administration from Växjö University. Lars Johansson is currently a board member of Ciencia Research and Carponovum AB. Lars Johansson holds no shares in the Company and is independent in relation to the Company, its management, and major shareholders.Jack Bradley, born 1991, has more than a decade of experience in the investment management business. He joined Noster Capital in 2014, and became a Partner and Head of Research in 2017 covering a broad geographical and market-cap investment universe, frequently giving input to company management teams on investor communication and investor relations strategy. He holds a degree in modern history from the University of Oxford. He is a resident of Norway and a British Citizen. Jack Bradley holds no shares in the Company, but Noster Capital (where he is a Partner) holds 3 055 423 shares in the Company. Jack Bradley is independent in relation to the Company, its management, and major shareholders.Daniel Kaufman, born 1968, has been a serial entrepreneur for the past 35 years, starting over a dozen companies, mostly in the technology sector. In the past 6 years, he shifted his focus to investing in public companies, with a focus on small cap value, and a recent large concentration in healthcare. Over these 6 years, his investment returns have exceeded 50% annually. He currently holds 5%+ positions in Harrow Inc. (HROW), Delcath Systems Inc. (DCTH) and Abeona Therapeutics (ABEO). Daniel Kaufman graduated from Williams College with a degree in political economy. Daniel Kaufman holds 1 409 456 shares in the Company and is independent in relation to the Company, its management, and major shareholders.공시 • Apr 18Moberg Pharma AB (Publ) Announces Board Members Not Standing for Re-ElectionsMoberg Pharma AB (publ) announced that Jonas Ekblom, Otto Skolling and Nikolaj Sørensen have informed the nomination committee that they are not available for re-election at its Annual General Meeting to be held on May 21, 2026.공시 • Mar 13Moberg Pharma AB Secures Additional Terbinafine Supplier For Mob-015Moberg Pharma AB announced that an additional supplier of terbinafine has been approved for MOB-015 (drug for nail fungus). The regulatory approval process, initiated in April 2024, has now been positively completed. As a result, Moberg Pharma has thereby secured two alternative suppliers of terbinafine, each with the capacity to meet the company's global demand for terbinafine. This is in line with the company's overall quality efforts, ensuring a stable supply of the active ingredient.공시 • Nov 28+ 3 more updatesMoberg Pharma AB (publ) to Report Q2, 2026 Results on Aug 13, 2026Moberg Pharma AB (publ) announced that they will report Q2, 2026 results on Aug 13, 2026공시 • Oct 31Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026.공시 • Sep 30Moberg Pharma AB (publ) Approves Board ElectionsMoberg Pharma AB (publ) at its Extraordinary General Meeting held on September 29, 2025 approved the election of Fredrik Blom and Mona Zhang as new members of the Board of Directors for the period until the end of the next Annual General Meeting. Thus, the Board of Directors of the Company will, for the period until the next Annual General Meeting, consist of Jonas Ekblom (chairman of the board of directors), Nikolaj Sörensen, Isabelle Ducellier, Otto Skolling, Richard Ding, Fredrik Blom and Mona Zhang.Mona Zhang was born in 1981 and holds an MBA from Rotman and a bachelor's degree in electrical engineering from Beijing Institute of Technology. Mona Zhang has more than 15 years of experience in global investment management and corporate governance. Mona is the Founder and Managing Partner of Trunity Partners Ltd., a portfolio management firm registered with the Ontario Securities Commission in Canada, where she is responsible for capital allocation, operations, and compliance. Previously, she worked at Mackenzie Investments as a Portfolio Manager on the Global Equity and Income Team, focusing on investment research, portfolio construction, and risk oversight. Earlier in her career, she was with Burgundy Asset Management, specializing in international equity analysis. Today, Mona serves on the Boards of the Canadian Business History Association and the International Agama Zen Practice Centre. She is also a guest lecturer at the Rotman School of Management, University of Toronto. She is a CFA charterholder. Mona holds no shares in the Company as of the day of this notice and is independent in relation to the Company, its management and major shareholders.Fredrik Blom was born in 1970 and holds a master's degree in financial economics from Stockholm University. Throughout his professional career, Fredrik has primarily worked in sales, often within entrepreneurially driven companies. He has co-founded several companies, one of them is Svenska Studenthus, a real estate company focused on rental and student housing, which merged with K2A Fastigheter prior to the company's IPO on Nasdaq Stockholm in 2019. Fredrik has extensive experience in starting companies and developing their initial cash flows. Other companies Fredrik has co-founded and served on the board of include Jeff Fastigheter and RAW Properties. Fredrik holds 926,000 shares in the Company, directly and indirectly, as of the day of this notice. Fredrik is independent in relation to the Company, its management and major shareholders.공시 • Jun 25Moberg Pharma AB (Publ) Announces Management ChangesMoberg Pharma AB (publ) announced that in connection with the reorganization, Anders Bröijersén, Chief Medical Officer, and Robert Ehrl, Head of Supply, are leaving Moberg Pharma and the management team. Going forward, supply is incorporated into Christina Erixon's existing area of responsibility. The company's medical expertise is secured through consultants. Following these changes, Moberg Pharma's management team consists of Anna Ljung, Mark Beveridge, Annica Magnusson, and Christina Erixon.공시 • Dec 18Moberg Pharma AB (Publ) Secures New Terbinafine SupplierMoberg Pharma AB (publ) announces that a new terbinafine supplier has been secured for MOB-015 (drug for nail fungus). As a result, terbinafine availability is no longer a limiting factor for the company's launch plans. Over the past year, Moberg Pharma qualified a new terbinafine manufacturer with an authorized EU Certificate of Suitability (CEP) now available for MOB-015. Three product batches have been produced using terbinafine from the new supplier where available stability data confirm the shelf-life profile of MOB-015. The status is unchanged for the previously communicated approval process regarding the first additional terbinafine supplier, submitted in April. Moberg Pharma has earlier responded to all questions received from the Medical Products Agency and awaits the agency´s decision. As a result, Moberg Pharma expects to have several alternate terbinafine suppliers secured in the near future. Each of these suppliers has the capacity to meet the company's global terbinafine demand.공시 • Nov 08Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025.공시 • Oct 23+ 2 more updatesMoberg Pharma AB (publ) to Report First Half, 2025 Results on Aug 12, 2025Moberg Pharma AB (publ) announced that they will report first half, 2025 results on Aug 12, 2025공시 • Oct 11Moberg Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 11, 2025Moberg Pharma AB (publ) announced that they will report fiscal year 2024 results on Feb 11, 2025공시 • Sep 13Moberg Pharma AB (publ) Receives Information About Clinical Cure in a Subset of Patients in the Ongoing North American Phase 3 Study for MOB-015 Against Nail FungusMoberg Pharma AB (publ) announced that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved clinical cure in this blinded subset of patients is lower than the company's expectations, which necessitates that Moberg Pharma inform the market about this fact. The North American Phase 3 study is ongoing at 33 study centers in the US and Canada, including a total of 384 patients. The study constitutes an essential part of the clinical data required for the registration and commercialization of MOB-015 in the US and differs from previous studies with MOB-015, which is the basis for drug approval in 13 EU countries, by reducing the dosage - 8 weeks daily dosing followed by weekly maintenance treatment for 40 weeks, compared to daily dosing throughout the entire treatment period. In the process of preparing the database for upcoming topline data, the company has received information regarding clinical cure in a subset of patients in the study. Clinical cure is one of three parameters that together constitute the study's primary treatment goal, complete cure. All three parameters; clinical cure, negative fungal culture, and negative microscopy, need to be met for a patient to be considered completely cured. No information has been obtained about the other study parameters included in complete cure. The information obtained is blinded; no information has been received regarding which patient received active treatment or how many patients in the data subset received active treatment (patients in the study are randomized 2:1 to treatment with MOB-015 and vehicle). The total number of patients who have achieved clinical cure in this subset of patients is lower than the company's expectations, and Moberg Pharma assesses that the risk of not being able to commercialize the product in the US based on this study has significantly increased, which requires the company to inform the market of this fact. It is an absolute priority to protect the integrity of the study data, both as not to undermine the possibilities of using study results in discussions with regulatory authorities, and as there are patients with ongoing treatment in the study. Moberg Pharma will not speculate on possible outcomes or what this means for the future potential of MOB-015 and will await topline results to avoid drawing premature conclusions.공시 • May 16Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board MemberMoberg Pharma AB (publ) at its Annual General Meeting held on May 14, 2024, approved the election of Jonas Ekblom as board member for a period until the end of the next Annual General Meeting.공시 • May 08Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized ProcedureMoberg Pharma AB announced that MOB-015 has received national approvals for all countries included in the decentralized procedure. MOB-015 is thus approved for the treatment of mild to moderate fungal infections of the nails in adults in 13 European countries. National approvals follow the completion of the decentralized procedure with a positive result where MOB-015 is recommended for approval in 13 European countries. The following EU countries are included: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. MOB-015 can be obtained with a prescription (Rx) in the Czech Republic, Denmark, Finland, France, Ireland and Spain, while it's approved as a non-prescription medicinal product, i.e. over-the-counter (OTC) in Austria, Belgium, Hungary, Italy, the Netherlands, Norway and Sweden.공시 • Aug 04+ 2 more updatesMoberg Pharma AB (publ) to Report Nine Months, 2024 Results on Nov 12, 2024Moberg Pharma AB (publ) announced that they will report nine months, 2024 results on Nov 12, 2024매출 및 비용 세부 내역Moberg Pharma가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:MBGP.F 매출, 비용 및 순이익 (SEK Millions)날짜매출순이익일반관리비연구개발비31 Mar 2615-2631531 Dec 2514-2732430 Sep 2512-2583230330 Jun 2512-2553030331 Mar 2513-2512830231 Dec 2410-2552930230 Sep 249-1830230 Jun 245-2330331 Mar 241-2327431 Dec 230-2125430 Sep 230-1823330 Jun 230-1622231 Mar 230-1622131 Dec 220-1621130 Sep 220-1720230 Jun 220-1619231 Mar 220-1618331 Dec 210-1619330 Sep 2134821530 Jun 2134721631 Mar 2134522631 Dec 2034722630 Jun 20502024730 Jun 1931-8311331 Mar 19455312691831 Dec 185-28261330 Sep 1834192171630 Jun 18340192101531 Mar 1833462061431 Dec 17439112611430 Sep 17438-12681530 Jun 1743402531531 Mar 17369352181331 Dec 16334332011230 Sep 16299361811530 Jun 16261321681531 Mar 1628291651931 Dec 15286261592330 Sep 15276251582230 Jun 152602015025양질의 수익: MBGP.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: MBGP.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: MBGP.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 59% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 MBGP.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: MBGP.F은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-4.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: MBGP.F는 현재 수익성이 없으므로 자본 수익률이 음수(-3.87%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/05 04:12종가2026/06/02 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Moberg Pharma AB (publ)는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bjorn RydellABG Sundal Collier SponsoredKlas PykNordea MarketsMats HyttingeRedeye1명의 분석가 더 보기
공시 • Nov 28+ 3 more updatesMoberg Pharma AB (publ) to Report Q2, 2026 Results on Aug 13, 2026Moberg Pharma AB (publ) announced that they will report Q2, 2026 results on Aug 13, 2026
공시 • Oct 23+ 2 more updatesMoberg Pharma AB (publ) to Report First Half, 2025 Results on Aug 12, 2025Moberg Pharma AB (publ) announced that they will report first half, 2025 results on Aug 12, 2025
공시 • Oct 11Moberg Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 11, 2025Moberg Pharma AB (publ) announced that they will report fiscal year 2024 results on Feb 11, 2025
공시 • Aug 04+ 2 more updatesMoberg Pharma AB (publ) to Report Nine Months, 2024 Results on Nov 12, 2024Moberg Pharma AB (publ) announced that they will report nine months, 2024 results on Nov 12, 2024
공시 • May 23Moberg Pharma AB (Publ) Approves the Election of Board MembersOn May 21, 2026. Moberg Pharma AB (publ) held its Annual General Meeting. The Annual General Meeting resolved, in accordance with the proposal of the shareholder Noster Capital Master Fund Limited ("Noster Capital"), on election of Lars Johansson, Jack Bradley and Daniel Kaufman as board members, all for the period until the end of the next Annual General Meeting. Lars Johansson was elected, in accordance with the proposal of both the Nomination Committee and Noster Capital, as the new Chairman of the Board for the period until the end of the next Annual General Meeting. Lars Johansson, born 1966, has over 30 years of experience in pharmaceuticals and medtech. Lars Johansson has held leading roles within the J&J Group with increasing business area responsibility, including as CEO of the Nordic operations (Johnson & Johnson AB 2011-2019, and Janssen AB 2019-2021). Lars Johansson has also held board positions in Schain Research AB, ProstaLund AB, RLS AB, and Läkemedelsindustriföreningen (the Swedish Association of the Pharmaceutical Industry). Lars Johansson holds a master's degree in business administration from Växjö University. Lars Johansson is currently a board member of Ciencia Research and Carponovum AB. Lars Johansson holds no shares in the Company and is independent in relation to the Company, its management, and major shareholders.Jack Bradley, born 1991, has more than a decade of experience in the investment management business. He joined Noster Capital in 2014, and became a Partner and Head of Research in 2017 covering a broad geographical and market-cap investment universe, frequently giving input to company management teams on investor communication and investor relations strategy. He holds a degree in modern history from the University of Oxford. He is a resident of Norway and a British Citizen. Jack Bradley holds no shares in the Company, but Noster Capital (where he is a Partner) holds 3 055 423 shares in the Company. Jack Bradley is independent in relation to the Company, its management, and major shareholders.Daniel Kaufman, born 1968, has been a serial entrepreneur for the past 35 years, starting over a dozen companies, mostly in the technology sector. In the past 6 years, he shifted his focus to investing in public companies, with a focus on small cap value, and a recent large concentration in healthcare. Over these 6 years, his investment returns have exceeded 50% annually. He currently holds 5%+ positions in Harrow Inc. (HROW), Delcath Systems Inc. (DCTH) and Abeona Therapeutics (ABEO). Daniel Kaufman graduated from Williams College with a degree in political economy. Daniel Kaufman holds 1 409 456 shares in the Company and is independent in relation to the Company, its management, and major shareholders.
공시 • Apr 18Moberg Pharma AB (Publ) Announces Board Members Not Standing for Re-ElectionsMoberg Pharma AB (publ) announced that Jonas Ekblom, Otto Skolling and Nikolaj Sørensen have informed the nomination committee that they are not available for re-election at its Annual General Meeting to be held on May 21, 2026.
공시 • Mar 13Moberg Pharma AB Secures Additional Terbinafine Supplier For Mob-015Moberg Pharma AB announced that an additional supplier of terbinafine has been approved for MOB-015 (drug for nail fungus). The regulatory approval process, initiated in April 2024, has now been positively completed. As a result, Moberg Pharma has thereby secured two alternative suppliers of terbinafine, each with the capacity to meet the company's global demand for terbinafine. This is in line with the company's overall quality efforts, ensuring a stable supply of the active ingredient.
공시 • Nov 28+ 3 more updatesMoberg Pharma AB (publ) to Report Q2, 2026 Results on Aug 13, 2026Moberg Pharma AB (publ) announced that they will report Q2, 2026 results on Aug 13, 2026
공시 • Oct 31Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026.
공시 • Sep 30Moberg Pharma AB (publ) Approves Board ElectionsMoberg Pharma AB (publ) at its Extraordinary General Meeting held on September 29, 2025 approved the election of Fredrik Blom and Mona Zhang as new members of the Board of Directors for the period until the end of the next Annual General Meeting. Thus, the Board of Directors of the Company will, for the period until the next Annual General Meeting, consist of Jonas Ekblom (chairman of the board of directors), Nikolaj Sörensen, Isabelle Ducellier, Otto Skolling, Richard Ding, Fredrik Blom and Mona Zhang.Mona Zhang was born in 1981 and holds an MBA from Rotman and a bachelor's degree in electrical engineering from Beijing Institute of Technology. Mona Zhang has more than 15 years of experience in global investment management and corporate governance. Mona is the Founder and Managing Partner of Trunity Partners Ltd., a portfolio management firm registered with the Ontario Securities Commission in Canada, where she is responsible for capital allocation, operations, and compliance. Previously, she worked at Mackenzie Investments as a Portfolio Manager on the Global Equity and Income Team, focusing on investment research, portfolio construction, and risk oversight. Earlier in her career, she was with Burgundy Asset Management, specializing in international equity analysis. Today, Mona serves on the Boards of the Canadian Business History Association and the International Agama Zen Practice Centre. She is also a guest lecturer at the Rotman School of Management, University of Toronto. She is a CFA charterholder. Mona holds no shares in the Company as of the day of this notice and is independent in relation to the Company, its management and major shareholders.Fredrik Blom was born in 1970 and holds a master's degree in financial economics from Stockholm University. Throughout his professional career, Fredrik has primarily worked in sales, often within entrepreneurially driven companies. He has co-founded several companies, one of them is Svenska Studenthus, a real estate company focused on rental and student housing, which merged with K2A Fastigheter prior to the company's IPO on Nasdaq Stockholm in 2019. Fredrik has extensive experience in starting companies and developing their initial cash flows. Other companies Fredrik has co-founded and served on the board of include Jeff Fastigheter and RAW Properties. Fredrik holds 926,000 shares in the Company, directly and indirectly, as of the day of this notice. Fredrik is independent in relation to the Company, its management and major shareholders.
공시 • Jun 25Moberg Pharma AB (Publ) Announces Management ChangesMoberg Pharma AB (publ) announced that in connection with the reorganization, Anders Bröijersén, Chief Medical Officer, and Robert Ehrl, Head of Supply, are leaving Moberg Pharma and the management team. Going forward, supply is incorporated into Christina Erixon's existing area of responsibility. The company's medical expertise is secured through consultants. Following these changes, Moberg Pharma's management team consists of Anna Ljung, Mark Beveridge, Annica Magnusson, and Christina Erixon.
공시 • Dec 18Moberg Pharma AB (Publ) Secures New Terbinafine SupplierMoberg Pharma AB (publ) announces that a new terbinafine supplier has been secured for MOB-015 (drug for nail fungus). As a result, terbinafine availability is no longer a limiting factor for the company's launch plans. Over the past year, Moberg Pharma qualified a new terbinafine manufacturer with an authorized EU Certificate of Suitability (CEP) now available for MOB-015. Three product batches have been produced using terbinafine from the new supplier where available stability data confirm the shelf-life profile of MOB-015. The status is unchanged for the previously communicated approval process regarding the first additional terbinafine supplier, submitted in April. Moberg Pharma has earlier responded to all questions received from the Medical Products Agency and awaits the agency´s decision. As a result, Moberg Pharma expects to have several alternate terbinafine suppliers secured in the near future. Each of these suppliers has the capacity to meet the company's global terbinafine demand.
공시 • Nov 08Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025.
공시 • Oct 23+ 2 more updatesMoberg Pharma AB (publ) to Report First Half, 2025 Results on Aug 12, 2025Moberg Pharma AB (publ) announced that they will report first half, 2025 results on Aug 12, 2025
공시 • Oct 11Moberg Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 11, 2025Moberg Pharma AB (publ) announced that they will report fiscal year 2024 results on Feb 11, 2025
공시 • Sep 13Moberg Pharma AB (publ) Receives Information About Clinical Cure in a Subset of Patients in the Ongoing North American Phase 3 Study for MOB-015 Against Nail FungusMoberg Pharma AB (publ) announced that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved clinical cure in this blinded subset of patients is lower than the company's expectations, which necessitates that Moberg Pharma inform the market about this fact. The North American Phase 3 study is ongoing at 33 study centers in the US and Canada, including a total of 384 patients. The study constitutes an essential part of the clinical data required for the registration and commercialization of MOB-015 in the US and differs from previous studies with MOB-015, which is the basis for drug approval in 13 EU countries, by reducing the dosage - 8 weeks daily dosing followed by weekly maintenance treatment for 40 weeks, compared to daily dosing throughout the entire treatment period. In the process of preparing the database for upcoming topline data, the company has received information regarding clinical cure in a subset of patients in the study. Clinical cure is one of three parameters that together constitute the study's primary treatment goal, complete cure. All three parameters; clinical cure, negative fungal culture, and negative microscopy, need to be met for a patient to be considered completely cured. No information has been obtained about the other study parameters included in complete cure. The information obtained is blinded; no information has been received regarding which patient received active treatment or how many patients in the data subset received active treatment (patients in the study are randomized 2:1 to treatment with MOB-015 and vehicle). The total number of patients who have achieved clinical cure in this subset of patients is lower than the company's expectations, and Moberg Pharma assesses that the risk of not being able to commercialize the product in the US based on this study has significantly increased, which requires the company to inform the market of this fact. It is an absolute priority to protect the integrity of the study data, both as not to undermine the possibilities of using study results in discussions with regulatory authorities, and as there are patients with ongoing treatment in the study. Moberg Pharma will not speculate on possible outcomes or what this means for the future potential of MOB-015 and will await topline results to avoid drawing premature conclusions.
공시 • May 16Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board MemberMoberg Pharma AB (publ) at its Annual General Meeting held on May 14, 2024, approved the election of Jonas Ekblom as board member for a period until the end of the next Annual General Meeting.
공시 • May 08Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized ProcedureMoberg Pharma AB announced that MOB-015 has received national approvals for all countries included in the decentralized procedure. MOB-015 is thus approved for the treatment of mild to moderate fungal infections of the nails in adults in 13 European countries. National approvals follow the completion of the decentralized procedure with a positive result where MOB-015 is recommended for approval in 13 European countries. The following EU countries are included: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. MOB-015 can be obtained with a prescription (Rx) in the Czech Republic, Denmark, Finland, France, Ireland and Spain, while it's approved as a non-prescription medicinal product, i.e. over-the-counter (OTC) in Austria, Belgium, Hungary, Italy, the Netherlands, Norway and Sweden.
공시 • Aug 04+ 2 more updatesMoberg Pharma AB (publ) to Report Nine Months, 2024 Results on Nov 12, 2024Moberg Pharma AB (publ) announced that they will report nine months, 2024 results on Nov 12, 2024